SCHEMBL2163565

SCHEMBL2163565

CCC(Cl)Oc1cc2nnnc(Nc3ccc(C)cc3)c2cc1OC

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.50
KDR P35968 11/20 0.43
FLT1 P17948 1/20 0.43
EGFR P00533 13/20 0.42
LCK P06239 3/20 0.41
RET P07949 2/20 0.41
GAK O14976 1/20 0.41
RIPK2 O43353 1/20 0.41
STK10 O94804 1/20 0.41
FLT3 P36888 1/20 0.41
JAK3 P52333 1/20 0.41
AAK1 Q2M2I8 1/20 0.41
Q6ZSR9 Q6ZSR9 1/20 0.41
SLK Q9H2G2 1/20 0.41
IRAK4 Q9NWZ3 1/20 0.41
RPS6KA6 Q9UK32 1/20 0.41
ALK Q9UM73 1/20 0.41
ERBB2 P04626 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2163493 0.92 KDR (0.54) KDRFLT1EGFRLCKERBB2
SCHEMBL2164524 0.91 EGFR (0.53) SLC2A1KDRFLT1EGFRLCK
SCHEMBL2163645 0.90 EGFR (0.51) KDRFLT1EGFRLCKRET
SCHEMBL2163629 0.88 EGFR (0.49) KDRFLT1EGFRLCKGAK
SCHEMBL2163097 0.88 KDR (0.48) KDRFLT1EGFRRETERBB2
SCHEMBL2163900 0.86 EGFR (0.43) KDRFLT1EGFRLCKRET
SCHEMBL2163601 0.86 EGFR (0.42) KDRFLT1EGFRLCKGAK
SCHEMBL2164278 0.85 KDR (0.45) KDREGFRLCKRETGAK
SCHEMBL2164226 0.85 EGFR (0.58) KDREGFRERBB2
SCHEMBL2165591 0.85 EGFR (0.56) KDREGFRLCKERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349835-B2 Aromatic ring fused triazine derivatives and uses thereof SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2013-01-08 US claimed
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-07-28 US claimed
EP-2251332-A1 THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF Shenyang Pharmaceutical University (CN) 2010-11-17 EP claimed
US-8349835-B2 Aromatic ring fused triazine derivatives and uses thereof SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2013-01-08 US disclosed
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-07-28 US disclosed
EP-2251332-A1 THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF Shenyang Pharmaceutical University (CN) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF KDR, FLT1, FLT4 SLC2A1 1656/4885KDR 1/4885FLT1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.